Ref ID: 19504
Author:
K Takeda1*, Y Imamura1, S Ide1, T Takazono1, K Kosai1, Y Morinaga1,2, S Nakamura1, S Kurihara1,
M Tsukamoto1, T Miyazaki1, K Izumikawa1, K Yanagihara1,2, T Tashiro1, K Kangawa3, S Kohno1
Author address:
1Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of
Biomedical Sciences, Nagasaki, Japan
2Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
3National Cardiovascular Center Res
Full conference title:
6th Advances Against Aspergillosis 2014
Abstract:
Background:
Invasive pulmonary aspergillosis (IPA) occurs in immunocompromised patients and its mortality
rate is quite high. Antifungal prophylaxis is commonly used, however, its efficacy and tolerability
are insufficient.
Ghrelin is a peptide hormone that is produced mainly from stomach. It increases appetite and
stimulates food intake in humans. It has also been shown to have an effect on inflammation and the
immune system. In this study, we examined the effect of ghrelin in a mouse model of pulmonary
aspergillosis.
Methods:
Seven-weeks-old female ICR mice were given 200 mg/kg cortisone acetate for immunosuppression
at day 1 to 3. Mice were challenged with Aspergillus fumigatus conidia intratracheally at day 2.
Ghrelin administration was initiated at day 0, and continued daily for 9 days. Survival rate were
monitored throughout the study. In addition, mice were sacrificed on day 6 for fungal burden
analysis, histopathological examination and cytokine measurement.
Results:
Survival rate was significantly improved in ghreline-treated group (63%) compared with untreated
group (0%). Body weight of ghrelin-treated group was significantly heavier than that of untreated
group. Recovered fungal cell numbers from lung tissue were not significantly different in both
groups.
Conclusions:
Ghrelin showed preventive effect in the IPA mouse model. Since ghrelin didn’t show anti-fungal
activity, further studies for the mechanism of action of ghrelin is needed.
NOTE: THIS ABSTRACT HAS BEEN SELECTED FOR ORAL PRESENTATION.
Abstract Number: 32
Conference Year: 2014
Link to conference website: http://www.AAA2014.org
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a